Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40523 Elevation Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1771427 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-42479 HENNESSY CAPITAL INVESTMENT CORP. VII (Exact Name of Registrant as Specified in Its Charter) | Caym ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33624 SINTX Technologies, Inc. (Exact name of registrant as specified in its charter) DELAWARE 84-1375299 (State or other jurisdiction (IRS Employer of incorporat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-42479 HENNESSY CAPITAL INVESTMENT CORP. VII (Exact Name of Registrant as Specified in Its Charter) | Caym ...

Exhibit 99.1 Workhorse Group Reports First Quarter 2025 Results CINCINNATI, May 15, 2025 – Workhorse Group Inc. (Nasdaq: WKHS) ("Workhorse" or "the Company"), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today reported financial results for the first quarter ended March 31, 2025. Management Commentary "We continue to deliver high-quality electric trucks and build strong momentum as customer interest grows," said Workhorse CEO Rick Dauch. "Our W56' ...

Financial Performance - Revenue for the quarter ended March 31, 2025, was $57 thousand, a slight increase from $56 thousand in the same period in 2024[10] - Total revenue for the three months ended March 31, 2025, was $57,000, a slight increase from $56,000 in the same period of 2024, representing a growth of approximately 1.79%[24] - The net income for the quarter was $21.5 million, significantly improved from a net loss of $5.0 million in the same period in 2024, driven by a change in fair value of warrant liability[12] - The net income for Q1 2025 was $21,490,000, compared to a net loss of $4,983,000 in Q1 2024, indicating a significant turnaround[24] - Net income per share of common stock, basic, was $2.17 in Q1 2025, compared to a loss of $5.92 per share in Q1 2024[24] - The change in fair value of warrant liability contributed $26,513,000 to the income statement in Q1 2025, with no comparable figure in Q1 2024[24] Expenses - Research and development (R&D) expenses for the quarter totaled $2.5 million, up from $1.9 million in the comparable period in 2024, primarily due to increased expenses related to virology programs[10] - Research and development expenses increased to $2,506,000 in Q1 2025, up from $1,912,000 in Q1 2024, reflecting a rise of about 30.96%[24] - General and administrative (G&A) expenses decreased to $2.8 million from $3.4 million in the same period in 2024, mainly due to reduced consulting fees[11] - General and administrative expenses decreased to $2,754,000 in Q1 2025, down from $3,356,000 in Q1 2024, a reduction of approximately 17.91%[24] Cash and Assets - As of March 31, 2025, Traws Pharma had cash, cash equivalents, and short-term investments of approximately $15.9 million, down from $21.3 million as of December 31, 2024[9] - Total current assets decreased to $18,856,000 as of March 31, 2025, from $24,951,000 as of December 31, 2024, a decline of approximately 24.5%[22] - Stockholders' equity improved to $6,000,000 as of March 31, 2025, compared to a deficit of $31,630,000 as of December 31, 2024[22] Liabilities - Total liabilities significantly decreased to $13,063,000 as of March 31, 2025, down from $56,592,000 as of December 31, 2024, a reduction of about 76.98%[22] Product Development and Partnerships - Traws Pharma is preparing to submit a briefing package for ratutrelvir to regulatory authorities in Q2 2025, targeting acute COVID treatment and Long COVID[6] - Tivoxavir marboxil (TXM) is positioned for a multi-billion dollar market opportunity in the U.S. for bird flu and seasonal flu, with preparations underway for finalizing the development plan[7] - Phase 1 data for TXM indicated that it maintained plasma blood levels above the EC90 for approximately three weeks after a single oral dose, supporting its use as a single-dose treatment[7] - Ratutrelvir's pharmacokinetic profile showed maintenance of target blood plasma levels approximately 13 times above the EC50, indicating potential effectiveness against COVID-19[15] - Traws Pharma is seeking partnership opportunities for its legacy oncology assets, narazaciclib and rigosertib[6]

Financial Performance - Revenue for the quarter ended March 31, 2025, was $57 thousand, a slight increase from $56 thousand for the same period in 2024[10] - Total revenue for the three months ended March 31, 2025, was $57,000, a slight increase from $56,000 in the same period of 2024, representing a growth of approximately 1.79%[24] - The net income for the quarter was $21.5 million, significantly improved from a net loss of $5.0 million in the same quarter of 2024, driven by a change in fair value of warrant liability[12] - The net income for Q1 2025 was $21,490,000, compared to a net loss of $4,983,000 in Q1 2024, indicating a significant turnaround[24] - Net income per share of common stock for Q1 2025 was $2.17, compared to a loss of $5.92 per share in Q1 2024[24] Expenses - Research and development (R&D) expenses for the quarter totaled $2.5 million, up from $1.9 million in the comparable period in 2024, primarily due to increased expenses related to virology programs[10] - Research and development expenses increased to $2,506,000 in Q1 2025, up from $1,912,000 in Q1 2024, reflecting a rise of 30.96%[24] - General and administrative (G&A) expenses decreased to $2.8 million from $3.4 million in the same period in 2024, mainly due to reduced consulting fees[11] - General and administrative expenses decreased to $2,754,000 in Q1 2025, down from $3,356,000 in Q1 2024, a reduction of 17.91%[24] Assets and Liabilities - As of March 31, 2025, Traws Pharma had cash, cash equivalents, and short-term investments of approximately $15.9 million, down from $21.3 million as of December 31, 2024[9] - Total current assets decreased to $18,856,000 as of March 31, 2025, down from $24,951,000 as of December 31, 2024, a decline of 24.43%[22] - Total liabilities significantly decreased to $13,063,000 as of March 31, 2025, compared to $56,592,000 as of December 31, 2024, a reduction of 76.98%[22] - Stockholders' equity improved to $6,000,000 as of March 31, 2025, from a deficit of $31,630,000 as of December 31, 2024[22] Product Development and Regulatory Activities - Traws Pharma is preparing to submit a briefing package for ratutrelvir to regulatory authorities in Q2 2025, targeting acute COVID treatment and Long COVID prevention[6] - Tivoxavir marboxil (TXM) is positioned for a multi-billion dollar market opportunity in the U.S. for bird flu and seasonal flu treatments, with ongoing preparations for regulatory approval[7] - Phase 1 data for TXM indicated that it maintained plasma blood levels above the EC90 for approximately three weeks after a single oral dose, supporting its use as a single-dose treatment[7] - Ratutrelvir's pharmacokinetic profile showed maintenance of target blood plasma levels approximately 13 times above the EC50, indicating potential effectiveness against COVID-19[15] Strategic Initiatives - Traws Pharma is seeking partnership opportunities for its legacy oncology assets, narazaciclib and rigosertib[6] Changes in Fair Value - The change in fair value of warrant liability contributed $26,513,000 to the income statement in Q1 2025, with no comparable figure in Q1 2024[24] Shareholder Information - The weighted-average shares of common stock outstanding increased to 6,965,927 in Q1 2025, compared to 841,738 in Q1 2024, reflecting a substantial increase in shares[24]

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-39114 Galera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1454898 (State ...

Revenue and Sales Performance - Revenue of $165.6 billion increased by 2.5%, or 4.0% in constant currency (cc) [6] - Global eCommerce sales grew 22%, driven by store-fulfilled pickup & delivery and marketplace [7] - Walmart U.S. comp sales rose by 4.5%, with strong performance in health & wellness and grocery [14] - Walmart's net sales for the three months ended April 30, 2025, were $163,981 million, representing a 2.5% increase from $159,938 million in the same period of 2024 [34] - Walmart U.S. net sales for the three months ended April 30, 2025, were $112,163 million, a 3.2% increase from $108,670 million in the same period of 2024 [37] - Walmart International net sales decreased by 0.3% to $29,754 million compared to $29,833 million in the prior year [37] - Sam's Club U.S. net sales increased by 2.9% to $22,064 million from $21,435 million year-over-year [37] - Consolidated net sales for Walmart were $163,981 million, reflecting a 2.5% increase from $159,938 million in the previous year [37] - U.S. comparable sales with fuel increased by 4.4% for the 13 weeks ended May 2, 2025, compared to 3.8% in the prior year [38] Operating Income and Profitability - Operating income increased by $0.3 billion, or 4.3%, with adjusted operating income growth of 3.0% (cc) [7] - Operating income increased by 4.3% to $7,135 million for the three months ended April 30, 2025, up from $6,841 million in the prior year [34] - Adjusted operating income for the consolidated segment was $7,135 million, a 4.4% increase from $6,841 million in the same period last year [37] - Operating income for Walmart International was $1,264 million, down 17.5% from $1,533 million in the previous year [37] - Operating income for the trailing twelve months ended April 30, 2025, was $29,642 million, up from $27,613 million in 2024 [65] Cash Flow and Financial Position - Operating cash flow increased by $1.2 billion to $5.4 billion, while free cash flow rose by $0.9 billion to $0.4 billion [12] - Cash flows from operating activities for the three months ended April 30, 2025, were $5,411 million, compared to $4,249 million in 2024, indicating improved cash generation [36] - Free cash flow for the three months ended April 30, 2025, was $425 million, an increase of $852 million compared to a negative $427 million in the prior year [48] - The company experienced a net cash used in investing activities of $5,093 million for the three months ended April 30, 2025, compared to $4,409 million in 2024 [36] Membership and Other Income - Membership income grew by 14.8%, contributing to a 3.7% increase in total membership and other income [7] Inventory and Assets - Inventory increased by 3.8% to $57.5 billion, maintaining healthy in-stock levels [12] - Walmart's inventories increased to $57,467 million as of April 30, 2025, from $56,435 million at the end of January 2025 [35] - Total assets as of April 30, 2025, were $262,372 million, a slight increase from $260,823 million at the end of January 2025 [35] - Average total assets increased to $258,213 million for the trailing twelve months ended April 30, 2025, compared to $249,554 million in 2024 [63] - Total assets as of April 30, 2025, were $262,372 million, an increase from $254,054 million in 2024 [65] Net Income and Earnings Per Share - Consolidated net income attributable to Walmart decreased by 12.1% to $4,487 million for the three months ended April 30, 2025, compared to $5,104 million in 2024 [34] - Consolidated net income for the trailing twelve months ended April 30, 2025, was $19,489 million, down from $19,681 million in 2024 [63] - Reported EPS for the three months ended April 30, 2025, was $0.56, with adjusted EPS at $0.61 after accounting for unrealized and realized gains and losses [56] - For the three months ended April 30, 2024, reported EPS was $0.63, with adjusted EPS at $0.60 after adjustments for unrealized and realized gains and losses and business reorganization charges [57] Tax and Returns - The effective tax rate for the three months ended April 30, 2025, was 22.6%, adjusted to 22.8% after accounting for investment gains and losses [56] - Return on assets (ROA) decreased to 7.5% for the trailing twelve months ended April 30, 2025, down from 7.9% in 2024, primarily due to increased average total assets and a slight decline in net income [60] - Return on investment (ROI) increased to 15.3% for the trailing twelve months ended April 30, 2025, compared to 15.0% in 2024, driven by higher operating income [60] Guidance and Future Expectations - The company expects net sales for Q2 FY26 to increase by 3.5% to 4.5% in constant currency [23] - Fiscal year 2026 guidance remains unchanged, with net sales expected to be between $674.5 billion and $681 billion [27] Debt and Liabilities - The company reported a decrease in interest expense on debt by 13.1%, totaling $519 million for the three months ended April 30, 2025 [34] - Walmart's total current liabilities increased to $102,920 million as of April 30, 2025, compared to $96,584 million at the end of January 2025 [35] - Average invested capital rose to $298,082 million for the trailing twelve months ended April 30, 2025, compared to $284,415 million in 2024 [65]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 May 15, 2025 PLDT INC. (Translation of registrant's name into English) Ramon Cojuangco Building Makati Avenue, Makati City Philippines (Address of registrant's principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ SIGNA ...